Analysts expect Humana Inc (NYSE:HUM) to report earnings of $2.00 per share for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Humana’s earnings, with estimates ranging from $1.95 to $2.06. Humana reported earnings of $2.09 per share in the same quarter last year, which indicates a negative year over year growth rate of 4.3%. The firm is scheduled to report its next earnings report before the market opens on Wednesday, February 7th.

According to Zacks, analysts expect that Humana will report full year earnings of $11.63 per share for the current year, with EPS estimates ranging from $11.60 to $11.70. For the next financial year, analysts anticipate that the company will post earnings of $12.58 per share, with EPS estimates ranging from $11.95 to $14.13. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Humana.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share for the quarter, topping the consensus estimate of $3.27 by $0.12. Humana had a net margin of 3.49% and a return on equity of 15.99%. The firm had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $13.41 billion. During the same quarter in the previous year, the company posted $3.18 EPS. Humana’s revenue was down 3.0% on a year-over-year basis.

Several research firms recently weighed in on HUM. Jefferies Group upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $221.00 price objective for the company in a research report on Friday. Goldman Sachs Group began coverage on shares of Humana in a research report on Wednesday, January 3rd. They set a “buy” rating and a $305.00 target price for the company. JPMorgan Chase & Co. cut shares of Humana from an “overweight” rating to a “neutral” rating and set a $253.00 target price for the company. in a research report on Monday, October 9th. ValuEngine cut shares of Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Finally, Royal Bank of Canada reiterated a “hold” rating and set a $245.00 target price on shares of Humana in a research report on Tuesday, October 10th. Ten analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Humana has an average rating of “Buy” and an average target price of $258.90.

Humana (NYSE HUM) opened at $268.02 on Friday. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 0.35. Humana has a 1 year low of $186.25 and a 1 year high of $271.99. The firm has a market cap of $37,887.92, a P/E ratio of 21.09, a P/E/G ratio of 1.73 and a beta of 0.88.

Humana announced that its board has approved a share buyback plan on Thursday, December 14th that permits the company to repurchase $3.00 billion in shares. This repurchase authorization permits the insurance provider to buy shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date is Thursday, December 28th. Humana’s dividend payout ratio is currently 12.59%.

In related news, SVP Jody L. Bilney sold 7,054 shares of the company’s stock in a transaction on Monday, December 18th. The shares were sold at an average price of $247.89, for a total value of $1,748,616.06. Following the completion of the sale, the senior vice president now owns 11,704 shares in the company, valued at approximately $2,901,304.56. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Brian P. Leclaire sold 1,679 shares of the company’s stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $245.97, for a total transaction of $412,983.63. Following the completion of the sale, the senior vice president now owns 9,888 shares of the company’s stock, valued at approximately $2,432,151.36. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,115 shares of company stock valued at $2,501,627. 0.80% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Humana by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 9,892,635 shares of the insurance provider’s stock worth $2,380,366,000 after purchasing an additional 157,868 shares during the period. FMR LLC boosted its stake in Humana by 29.3% in the 2nd quarter. FMR LLC now owns 6,530,063 shares of the insurance provider’s stock worth $1,571,264,000 after purchasing an additional 1,479,210 shares during the period. Capital Research Global Investors boosted its stake in Humana by 9.7% in the 2nd quarter. Capital Research Global Investors now owns 3,907,333 shares of the insurance provider’s stock worth $940,182,000 after purchasing an additional 346,069 shares during the period. Renaissance Technologies LLC boosted its stake in Humana by 1.5% in the 2nd quarter. Renaissance Technologies LLC now owns 2,731,100 shares of the insurance provider’s stock worth $657,157,000 after purchasing an additional 39,400 shares during the period. Finally, Janus Henderson Group PLC boosted its stake in Humana by 74.1% in the 3rd quarter. Janus Henderson Group PLC now owns 2,729,248 shares of the insurance provider’s stock worth $664,921,000 after purchasing an additional 1,161,661 shares during the period. Institutional investors and hedge funds own 94.01% of the company’s stock.

WARNING: This piece was first published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.watchlistnews.com/zacks-analysts-expect-humana-inc-hum-to-announce-2-00-earnings-per-share/1806478.html.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Get a free copy of the Zacks research report on Humana (HUM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.